Development and application of photo-thermal controllable LYTAC technology
Through the photothermal controllable LYTAC technology, photothermal-sensitive engineered bacteria are used to control the time and space expression of TfR-LYTAC in mice, solving the uncontrolled degradation problem caused by LYTAC and realizing the target protein PD-L1 Degradation, used for low-temperature photothermal therapy and immunotherapy, significantly inhibits the proliferation of tumor cells.
Patent Information
- Application Number
- CN202411074497.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-07
- Publication Date
- 2024-11-19
AI Technical Summary
LYTAC technology may lead to uncontrolled protein degradation, leading to systemic toxicity problems, limiting its application in clinical practice.
Develop a photothermal controllable LYTAC technology to prepare photothermal sensitivity by introducing TfR-LYTAC containing n-terminal PelB secretion signal sequence into E. coli MG1655 and coupling the FDA-approved photothermal agent indocyanine green on its surface. Engineering bacteria to achieve time and space expression regulation of TfR-LYTAC.
The controllable degradation of TfR-LYTAC was successfully achieved, and the expression of time and space in mice through the stimulation of the 808nm light source was achieved, which safely and effectively inhibited the proliferation of tumor cells and had broad application prospects in the field of biomedicine.
Smart Images

Figure CN118979052A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of modern biotechnology engineering, and specifically relates to the development and application of a photothermal controllable LYTAC technology. Background Art
[0002] Targeted protein degradation (TPD) is an emerging protein degradation technology in recent years, which has attracted great attention in the fields of chemical biology and drug discovery. According to different protein degradation pathways, it can be divided into lysosomal system and proteasomal pathway. Since the degradation targets of lysosomal protein degradation pathway cover intracellular and extracellular proteins, and can degrade protein polymers, organelles, etc., the selective degradation strategy of biological substances based on lysosomes has great potential, and the development of lysosome-based degraders will be an important direction for disease treatment through protein degradation.
[0003] Lysosome-targeting chimera (LYTAC) technology can simultaneously bind to the extracellular domain of extracellular proteins or membrane proteins, as well as lysosome-targeting receptors on the cell surface to form a ternary complex, and lead to internalization and degradation of proteins through endocytosis. Since extracellular proteins and membrane proteins account for about 40% of all encoded proteins and are key factors in neurodegenerative diseases, autoimmune diseases and cancer, LYTAC molecules with different mechanisms of action are potential good complements to PROTAC drugs, and are also emerging therapies that the biopharmaceutical community is eager to explore and develop.
[0004] However, LYTACs may cause uncontrolled degradation, leading to systemic toxicity issues, limiting the clinical application of LYTACs. Summary of the invention
[0005] The purpose of the present invention is to provide a method for constructing a photothermal-sensitive engineered bacterium that can introduce a photothermal-induced switch to achieve temporal and spatial expression regulation of TfR-LYTAC, in order to achieve controllable protein degradation by LYTAC.
[0006] In order to achieve the above technical effects, the present invention is implemented by the following technical solutions: Development of a photothermally controllable LYTAC technology, characterized in that it includes the following steps:
[0007] S1. TfR-LYTAC containing the N-terminal PelB secretion signal sequence was introduced into the pBV220 plasmid by digestion with EcoRI and BamHI, and ligated to obtain a thermosensitive plasmid expressing TfR-LYTAC;
[0008] S2, chemically transforming the thermosensitive plasmid into Escherichia coli MG1655 to obtain heat-controlled bacteria MG1655 (pBV220-TfR-LYTAC);
[0009] S3. The FDA-approved photothermal agent indocyanine green (ICG) was coupled to the surface of MG1655 (pBV220-TfR-LYTAC) bacteria to prepare photothermal-controlled photothermal-sensitive engineered bacteria (MG1655 (pBV220-TfR-LYTAC) @ICG).
[0010] Further, in S2, the thermosensitive plasmid was chemically transformed into Escherichia coli MG1655 to obtain the photothermal-controlled photothermal-triggered bacteria MG1655 (pBV220-TfR-LYTAC); the specific operation is as follows:
[0011] S2.1. Take out the competent cells MG1655 stored at -80℃ and melt them on ice; add 5μL of thermosensitive plasmid pBV220-TfR-LYTAC to 100μL of competent cells, ice bath for 30min, heat shock at 42℃ for 45S, add 900μL of liquid LB medium without resistance, place in a 37℃ shaker, treat at 200 rpm for 1h, then centrifuge at 1000g for 2min, remove 850μL of medium, blow the remaining LB medium evenly, spread it on the LB solid medium containing resistance, and culture it at 37℃ overnight; pick a single clone, place it in 10mL of liquid culture medium, place it in a 37℃ shaker, and culture it overnight at 200 rpm to obtain the photothermal-controlled photothermal-triggered bacteria MG1655 (pBV220-TfR-LYTAC).
[0012] Further, in S3, the FDA-approved photothermal agent indocyanine green (ICG) was coupled to the surface of MG1655 (pBV220-TfR-LYTAC) bacteria to prepare photothermal engineered bacteria (MG1655 (pBV220-TfR-LYTAC) @ICG); the specific operation is as follows:
[0013] S3.1, incubating the obtained photothermal triggered bacteria with NHS-ICG in a sodium bicarbonate solution with a pH of 8.2 to 8.4 at a molar ratio of 1:6 to 10 on ice overnight;
[0014] S3.2. Remove the free NHS-ICG in the bacterial suspension after overnight incubation at 4500-5500 rpm for 4-6 minutes to complete the labeling; then the photothermosensitive engineered bacteria (MG1655(pBV220-TfR-LYTAC)@ICG) can be obtained.
[0015] Another object of the present invention is to provide an application of a photothermally controllable LYTAC technology, characterized in that the photothermally controllable LYTAC technology is used in controllable protein degradation.
[0016] Furthermore, the photothermal controllable LYTAC technology is applied in the controllable degradation of proteins as follows: under the stimulation of 808nm light source, when the light intensity is 0.5W / cm 2 -1.5W / cm 2 The laser-driven heat generation has a high precision between the range, thereby achieving the temporal and spatial expression of TfR-LYTAC in mice, in order to achieve the purpose of controllable protein degradation by LYTAC.
[0017] The beneficial effects of the present invention are:
[0018] In this study, LYTAC was transformed into a photothermal engineered bacterium (MG1655(pBV220-TfR-LYTAC)@ICG), and a photothermal-induced switch was successfully introduced to achieve the temporal and spatial expression of TfR-LYTAC, in order to achieve the purpose of controllable protein degradation by LYTAC; at the same time, the system was used to control the spatiotemporal specific expression of the TfR-LYTAC gene and the degradation of the target protein PD-L1, realizing the combination of low-temperature photothermal therapy and immunotherapy for mouse tumors, and safely and effectively inhibiting the proliferation of tumor cells in vivo; it has broad application prospects in the fields of biomedicine and so on. BRIEF DESCRIPTION OF THE DRAWINGS
[0019] In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the accompanying drawings required for describing the embodiments will be briefly introduced below. Obviously, the accompanying drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other accompanying drawings can be obtained based on these accompanying drawings without paying creative work.
[0020] Figure 1 It is a gene expression map of the photothermal reaction bacteria induced by high temperature of the present invention;
[0021] Figure 2 It is a diagram of the photothermal properties of MG1655@ICG and the in vivo expression of photothermally controllable EGFP green fluorescence MG1655(EGFP)@ICG in mice in Example 2 of the present invention;
[0022] Figure 3 This is a diagram of low-temperature tumor immunotherapy of colon tumor-bearing mice mediated by MG1655 (TfR-LYTAC)@ICG in Example 3 of the present invention;
[0023] Figure 4The present invention relates to the development and characterization of the photothermal-induced TfR-LYTAC system in Example 4 and its application in cancer immunotherapy. DETAILED DESCRIPTION
[0024] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0025] Example 1
[0026] This embodiment describes the development of a photothermal controllable LYTAC technology, including the following steps:
[0027] S1. TfR-LYTAC containing the N-terminal PelB secretion signal sequence was introduced into the pBV220 plasmid by digestion with EcoRI and BamHI, and ligated to obtain a thermosensitive plasmid expressing TfR-LYTAC;
[0028] S2. Chemically transform the thermosensitive plasmid into Escherichia coli MG1655 to obtain heat-triggered bacteria MG1655 (pBV220-TfR-LYTAC); the operation is as follows:
[0029] S2.1. Take out the competent cells MG1655 stored at -80°C and thaw them on ice;
[0030] S2.2, add 5 μL of thermosensitive plasmid pBV220-TfR-LYTAC to 100 μL of competent cells, place on ice for 30 min, heat shock at 42°C for 45 s, add 900 μL of non-resistant liquid LB medium, place in a 37°C shaker, treat at 200 rpm for 1 h, then centrifuge at 1000 g for 2 min, remove 850 μL of medium,
[0031] S2.3. Evenly blow the remaining LB medium after removing 850 μL of medium, spread it on the LB solid medium containing resistance, and culture it at 37°C overnight; pick a single clone, place it in 10 mL of liquid culture medium, place it in a 37°C shaker, and culture it overnight at 200 rpm to obtain the photothermally controlled photothermal-triggered bacteria MG1655 (pBV220-TfR-LYTAC).
[0032] S3. The FDA-approved photothermal agent indocyanine green (ICG) was coupled to the surface of MG1655 (pBV220-TfR-LYTAC) bacteria to prepare the photothermal-controlled photothermal engineered bacteria (MG1655 (pBV220-TfR-LYTAC) @ICG); the operation is as follows:
[0033] S3.1, incubating the obtained photothermal triggered bacteria with NHS-ICG in a sodium bicarbonate solution with a pH of 8.2 to 8.4 at a molar ratio of 1:6 to 10 on ice overnight;
[0034] S3.2. Remove the free NHS-ICG in the bacterial suspension after overnight incubation at 4500-5500 rpm for 4-6 minutes to complete the labeling; then the photothermosensitive engineered bacteria (MG1655(pBV220-TfR-LYTAC)@ICG) can be obtained.
[0035] Embodiment 2:
[0036] This example describes the photothermal properties of MG1655@ICG and the in vivo expression verification of MG1655(EGFP)@ICG, as follows:
[0037] MG1655 transformed with pBV220-EGFP plasmid was cultured at 37°C overnight; then the bacteria were washed three times in PBS, centrifuged at 5000rpm for 5 minutes, and resuspended in PBS to a concentration of OD600 = 0.5; 100uL of bacterial suspension was subcutaneously injected into tumor-bearing mice, and laser irradiated for a specified time after 36h, and its temperature was quantified; the results showed that laser irradiation induced time-dependent expression of EGFP fluorescence intensity in mice (such as Figure 3 E); these results indicate that laser irradiation can precisely control protein expression as we designed.
[0038] Embodiment 3:
[0039] This example is about MG1655(TfR-LYTAC)@ICG-mediated low-temperature tumor immunotherapy in colon tumor-bearing mice;
[0040] MG1655@ICG (1×10 per mouse) 7CFU) were intravenously injected into tumor-bearing mice (n=9-10); the mice received (1) normal saline, (2) MG1655@ICG, (3) MG1655@ICG+laser for 8 minutes, (4) MG1655(LYTAC)@ICG+laser for 8 minutes, or (5) MG1655(LYTAC)@ICG+sc-laser for 20 minutes (3 laser treatments); the results showed that the laser precisely controlled the expression of LYTAC in vivo, achieved the degradation of LYTAC target protein PD-L1, inhibited the growth of tumors in mice, and significantly prolonged the survival of mice.
[0041] Example 4
[0042] like Figure 4 As shown in the figure, after inserting engineered bacteria containing the TfR-LYTAC gene into the temperature-sensitive gene circuit of mice, these engineered bacteria will be delivered to the tumor due to their tumor targeting ability; the tumor is then exposed to low-temperature photothermal irradiation to heat these intratumoral bacteria to 42-45°C to induce the expression of the TfR-LYTAC gene. The production and secretion of TfR-LYTAC promotes the degradation of PD-L1 in tumors and induces CD8 + T cell activation, ultimately leading to tumor cell death
[0043] The above description is only an exemplary embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions and improvements made within the spirit and principles of the present invention should be included in the protection scope of the present invention.
Claims
1. Development of a photothermal controllable LYTAC technology, It is characterized in that The following steps are involved: S1. TfR-LYTAC containing the N-terminal PelB secretion signal sequence was introduced into the pBV220 plasmid by digestion with EcoRI and BamHI, and ligated to obtain a thermosensitive plasmid expressing TfR-LYTAC; S2, chemically transforming the thermosensitive plasmid into Escherichia coli MG1655 to obtain heat-triggered bacteria MG1655 (pBV220-TfR-LYTAC); S3. The FDA-approved photothermal agent indocyanine green (ICG) was coupled to the surface of MG1655 (pBV220-TfR-LYTAC) bacteria to prepare photothermal engineered bacteria (MG1655 (pBV220-TfR-LYTAC) @ICG).
2. Development of the photothermally controllable LYTAC technology according to claim 1, It is characterized in that In S2, the thermosensitive plasmid was chemically transformed into Escherichia coli MG1655 to obtain the heat-controlled heat-triggered bacteria MG1655 (pBV220-TfR-LYTAC); the specific operation is as follows: S2.
1. Take out the competent cells MG1655 stored at -80°C and thaw them on ice; S2.2, add 5 μL of thermosensitive plasmid pBV220-TfR-LYTAC to 100 μL of competent cells, place on ice for 30 min, heat shock at 42°C for 45 s, add 900 μL of non-resistant liquid LB medium, place in a 37°C shaker, treat at 200 rpm for 1 h, then centrifuge at 1000 g for 2 min, remove 850 μL of medium, S2.
3. Evenly blow the remaining LB medium after removing 850 μL of medium, spread it on the LB solid medium containing resistance, and culture it at 37°C overnight; pick a single clone, place it in 10 mL of liquid culture medium, place it in a 37°C shaker, and culture it overnight at 200 rpm to obtain heat-controlled heat-triggered bacteria MG1655 (pBV220-TfR-LYTAC).
3. Development of the photothermally controllable LYTAC technology according to claim 1, It is characterized in that In S3, the FDA-approved photothermal agent indocyanine green (ICG) was coupled to the surface of MG1655 (pBV220-TfR-LYTAC) bacteria to prepare photothermal-controlled photothermal engineered bacteria (MG1655 (pBV220-TfR-LYTAC) @ICG); the specific operation is as follows: S3.1, incubating the obtained photothermal triggered bacteria with NHS-ICG in a sodium bicarbonate solution with a pH of 8.2 to 8.4 at a molar ratio of 1:6 to 10 on ice overnight; S3.
2. Remove the free NHS-ICG in the bacterial suspension after overnight incubation at 4500-5500 rpm for 4-6 minutes to complete the labeling; then the photothermosensitive engineered bacteria (MG1655(pBV220-TfR-LYTAC)@ICG) can be obtained.
4. Application of a photothermal controllable LYTAC technology, It is characterized in that The application of the photothermal controllable LYTAC technology in controllable protein degradation.
5. Application of the photothermal controllable LYTAC technology according to claim 4, It is characterized in that The application of the photothermal controllable LYTAC technology in the controllable degradation of proteins is as follows: under the stimulation of an 808nm light source, when the light intensity is 0.5W / cm 2 -1.5W / cm 2 The laser-driven heat generation has a high precision between the range, thereby achieving the temporal and spatial expression of TfR-LYTAC in mice, in order to achieve the purpose of controllable protein degradation by LYTAC.
